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Abstract Depression is a common condition among children
and adolescents, with lasting detrimental effects on health, and
social and occupational functioning. Despite being well-
positioned to treat depression, primary care providers (PCPs)
cite significant barriers. This review aims to summarize recent
evidence to provide practical guidance to PCPs on the man-
agement of pediatric depression in their practices. Following
identification and assessment, PCPs should provide general
initial management. Children and adolescents with mild de-
pression can be managed with active support and symptom
monitoring, while those with moderate-to-severe depression
can be treated with psychotherapy and/or antidepressants,
which may involve referral to mental health specialty care.
Less is known about the treatment of depression in children
under the age of 12 years, who may be candidates for earlier
referral to mental health specialty care. PCPs have the potential
to improve the recognition and management of depression in
young people, having lasting individual and societal benefits.
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Introduction
Depression is a common condition with up to 8 % of all
teenagers having met criteria for depression in the last year
[1]. In fact, by the age of 21 years, up to 14.8 % of individuals
have met criteria for a mood disorder [2]. Depression can have
significant lasting effects when diagnosed in childhood and
adolescence, and has been associated with later interpersonal
difficulties, early parenthood, impaired school performance,
unemployment, and other mental disorders and substance use
disorders [3–5]. Despite the significant burden of depression on
children and adolescents, only a minority receives any treat-
ment [6].
Primary care providers (PCPs) are well-positioned to im-
prove the recognition and treatment of depression among
children and adolescents, given the frequency with which
this population sees their PCPs and their comfort in
discussing health behavior concerns with their clinicians
[7]. Interventions delivered to depressed adolescents by
PCPs and within the primary care setting have demonstrated
effectiveness [8•]. However, many PCPs report significant
barriers to identifying and, particularly, to treating pediatric
depression in their practices, including issues of time, reim-
bursement, training, and access to mental health services [9].
Additionally, PCPs have cited the Food and Drug Adminis-
tration’s 2004 black box warning on the safety and efficacy
of antidepressants for children and adolescents, as a further
impediment to treating pediatric depression [9, 10]. Lastly,
significant practice and clinician differences between the
primary and specialty care settings do not allow for a simple
transfer of clinical guidelines developed for mental health
care settings [11]. Therefore, this review summarizes the
most recent literature on the management of pediatric de-
pression in an attempt to facilitate the treatment of this
disorder in primary care.
This review is based on recommendations by Guidelines
for Adolescent Depression in Primary Care (GLAD-PC), a
North American collaborative to develop guidelines for the
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management of adolescent depression in primary care
(Table 1). GLAD-PC was developed by researchers and
clinicians (including the senior authors of this review) from
the USA and Canada in response to the gap in clinical
guidance for PCPs. Details about the methods, recommen-
dations, and toolkit developed by the GLAD-PC collabora-
tive were published in Pediatrics in 2007 [12, 13] and at
www.gladpc.org. In this review, we summarize the key find-
ings and recommendations, and include evidence from addi-
tional research published since the completion of GLAD-PC
in 2007. The main focus of this review will be on the
treatment of depression in adolescents, in particular, who
have a higher prevalence of the disorder and for whom there
is a more extensive body of evidence. A small section is
dedicated to treatment of depression in children.
Identification and Assessment
While the focus of this review is on the treatment of pediatric
depression, the role of screening and assessment cannot be
overstated. Parental and adolescent complaints are a useful
indicator of depression, but reliance on these alone under-
identifies depression [12]. GLAD-PC recommends imple-
menting systematic depression identification procedures
[12], and the American Academy of Family Physicians
(AAFP) and US Preventive Services Task Force recom-
mends screening adolescents aged 12–18 years old for de-
pression when systems are in place to ensure accurate diag-
nosis, psychotherapy, and follow-up [14•]. It lists the Patient
Health Questionnaire for Adolescents and the Beck Depres-
sion Inventory for Primary Care as screening tools for de-
pression in adolescents that may be useful in primary care
[14•]. Screening for psychiatric comorbidities (including
substance use disorders, anxiety disorders, attention-
deficit/hyperactivity disorder, and bipolar disorder) is
also important in the assessment of pediatric depression
[12], and may guide management, as well as influence
treatment outcomes [15]. Lastly, assessment of pediatric
depression by PCPs should include an estimate of se-
verity to help determine management [12]. Table 2
highlights criteria used in the Diagnostic and Statistical
Manual Fourth Edition Text Revision for determining
the severity of a major depressive episode [16].
Table 1 Guidelines for Adolescent Depression in Primary Care (GLAD-PC) recommendations for the management of adolescent depression in
primary care
Initial Management Recommendation I: PCPs should educate and counsel families and patients about depression and options for the
management of the disorder (SOR = C, based on expert opinion). PCPs should also discuss limits of confidentiality
with the adolescent and family (SOR = C, based on expert opinion).
Recommendation II: PCPs should develop a treatment plan with patients and families (SOR = C, based on expert
opinion) and set specific treatment goals in key areas of functioning, including home, peer, and school settings
(SOR = C, based on expert opinion).
Recommendation III: The PCP should establish relevant links/collaboration with mental health resources in the
community (SOR = C, based on expert opinion), which may include patients and families who have dealt with
adolescent depression and are willing to serve as resources to other affected adolescents and their family members
(SOR = C, based on expert opinion).
Recommendation IV: All management must include the establishment of a safety plan, which includes restricting
lethal means, engaging a concerned third-party, and an emergency communication mechanism should the patient
deteriorate, become actively suicidal or dangerous to others, or experience an acute crisis associated with
psychosocial stressors, especially during the period of initial treatment when safety concerns are highest (SOR = C,
based on case control study and expert opinion).
Management Recommendation V: After initial diagnosis, in cases of mild depression, family PCPs should consider a period of
active support and monitoring before starting other evidence-based treatment (SOR = C, based on expert opinion).
Recommendation VII: If a PCP identifies an adolescent with moderate or severe depression or complicating
factors/conditions such as co-existing substance use disorder or psychosis, consultation with a mental health
specialist should be considered (SOR = C, based on expert opinion). Appropriate roles and responsibilities for
ongoing management by the PCP and mental health specialists should be communicated and agreed upon
(SOR = C, based on expert opinion). The patient and family should be consulted and approve of the roles
negotiated by the PCP and mental health professionals (SOR = C, based on expert opinion).
Recommendation VII: PCPs should recommend scientifically-tested and proven treatments (i.e., psychotherapies
such as CBT or IPT, and/or antidepressant treatment such as SSRIs) whenever possible and appropriate to achieve
the goals of the treatment plan (SOR = A, based on RCTs).
Recommendation VIII: family physicians should monitor for the emergence of adverse events during antidepressant
treatment (SSRIs) (SOR = C, based on expert opinion).
Data from Zuckerbrot et al. [12], with permission from GLAD-PC (www.gladpc.org)
SOR strength of recommendation, PCP primary care provider, CBT cognitive behavioral therapy, IPT interpersonal therapy, SSRI selective serotonin
reuptake inhibitor
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Initial Management
Initial management recommendations for the initial manage-
ment of pediatric depression should take into account treat-
ment preferences of patients/families, severity and urgency of
case presentation, availability of mental health services, and
the PCP’s skill level. A key conclusion of the GLAD-PC
collaborative was that the initial management and treatment
of adolescent depression can often be managed either by the
PCP alone or in collaboration with mental health specialty
care [12]. Components of initial management include (1)
psychoeducation for the adolescent and caregivers (e.g., signs
and symptoms of depression; natural history of the illness,
such as the likelihood of recurrence; impact on different areas
of functioning, such as at school, home, and with friends; and
options for treatment); (2) development of a treatment plan;
(3) linking patients and families to community resources,
including peer support; (4) safety planning; and (5) discussing
the limits of confidentiality. Education for patients and fami-
lies can be initially provided by the PCP or another primary
care staff person, and should be delivered in a variety of
formats (e.g., books, brochures, and websites). Additional
education can also be provided by advocacy and peer support
groups [12]. The GLAD-PC toolkit provides a number of
handouts and links to reputable websites, advocacy groups,
and peer support groups to meet this need. Examples of
organizations with websites that contain useful information
on pediatric depression include the National Institute of Men-
tal Health, the American Academy of Child and Adolescent
Psychiatry (AACAP), Families for Depression Awareness,
and the National Alliance for Mental Illness.
Treatment planning must be included as part of the initial
management [12]. In order to enhance adherence to treatment,
patients and families not only need to be educated about the
treatment options, but also feel comfortable with the treatment
plan. For example, if a patient or family is uncomfortable with
treatment with medications, they are unlikely to adhere to a
treatment plan focused around antidepressant management
alone. Patient and family preference plays a significant role
in adherence, as well as outcomes—as can expectation of the
benefit of treatment [17, 18].
Suicidality, including ideation, behaviors, or attempts, is
common among adolescents and even more so among adoles-
cents with depression [11, 19]. In studies of individuals who
have completed suicide, more than 50 % had a diagnosis of
depression [19], and rates of suicidal ideation and attempts
increase with longer duration of depression [20]. Therefore,
safety planning is a critical part of initial management of
depression and should be done immediately after diagnosis
when safety concerns are most significant [11]. In collaboration
with the adolescent, clinicians should develop an emergency
communication plan for handling of increased suicidality or
acute crises. This plan should be developed with all depressed
adolescents regardless of whether they report suicidality or not,
and should include a list of people and/or crisis services that the
adolescent can contact in case of increased suicidality.
After identifying a suicidal patient, the clinician should deter-
mine whether the patient’s risk is high enough to require imme-
diate hospitalization. For example, the physician should ask
about whether a clear and detailed plan for suicide has been
made by the teenager (i.e., method, timing, and location of
suicide have been identified). If the physician determines that
inpatient treatment is not warranted, the physician should ensure
that (1) adequate adult supervision and support are available; (2)
an adult agrees to safety-proof the home (i.e., limit access to
lethal means, including medications, sharp objects, and fire-
arms); (3) the patient and/or parents are aware of the disinhibiting
effects of illicit substances; and (4) a contingency plan is in place
and follow-up is established within a reasonable period of time
[19]. Despite controversy regarding increased suicidality among
adolescents receiving antidepressants, a recent clinical trial also
demonstrated that treatment with selective serotonin reuptake
inhibitors (SSRIs) and cognitive behavioral therapy (CBT) was
effective in decreasing suicidality in depressed youth [21•].
Therefore, initiating treatment in a timely manner also needs to
be discussed with patients and their families.
Table 2 Classification of Severity of Depression. Framework for grading
severity of depressive episodes. In both the Diagnostic and Statistical
Manual Fourth Edition Text Revision (DSM-IV-TR) and the International
Classification of Diseases-10, severity of depressive episodes is based on
the number, type, and severity of symptoms, as well as the degree of
functional impairment
DSM-IV-TR guidelines for grading severity depression
Category Mild Moderatea Severe
Number of symptoms 5–6 – “Most”
Severity of symptoms Mild – Severe
Degree of functional impairment Mild impairment or normal functioning
but with “substantial and unusual” effort
– “Clear-cut, observable disability”
In addition to the above framework, individual rating scales are associated with their own indicators of severity, as indicated in the Guidelines for
Adolescent Depression in Primary Care (GLAD-PC) toolkit
Reproduced from Zuckerbrot et al. [12], with permission from GLAD-PC (www.gladpc.org). Data from American Psychiatric Association [16].
a According to the DSM-IV-TR, Moderate episodes of depression “have a severity that is intermediate between mild and severe”
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Finally, the clinicians should discuss the limits of
confidentiality with each adolescent patient and his/her
parents/caregivers. Statutes regarding confidentiality vary
by jurisdiction, and clinicians should familiarize themselves
with their local legislation. In general, clinicians must respect
the confidentiality of the adolescent. However, clinicians




PCPs should consider a period of active support and monitor-
ing (6–8 weeks) using short validated scales before
recommending treatment with antidepressants or psychother-
apy in cases of mild depression [13]. Evidence from random-
ized controlled trials (RCTs) show that up to 20 % of depres-
sive youth respond to non-directive supportive therapy, rou-
tine specialist care, and/or regular symptom monitoring [13,
22•]. Furthermore, expert opinion and patient/family prefer-
ences indicate that active support and monitoring from family
physicians is an important therapeutic strategy [13, 23•]. Ac-
tive support and monitoring may include scheduling frequent
follow-up visits, encouraging participation in favorite extra-
curricular and school activities, referring to a peer support
group, setting self-management goals with patients and fam-
ilies, and providing them with educational materials [13].
Other resources for active monitoring can be found in the
GLAD-PC toolkit. In addition to its evidence in early mild
depression, active support and monitoring in primary care is
also essential in cases when adolescents refuse active treat-
ment [13]. More specific psychosocial interventions in prima-
ry care can improve depressive symptoms in adolescents, as
well as treatment adherence [7]. With a body of evidence in
adult depression, exercise is currently being investigated as a
specific treatment strategy in adolescents, with a range of
other benefits [24]. Treatment with antidepressants and/or
psychotherapy should be considered if symptoms do not
improve with active support and monitoring.
Moderate-to-Severe Depression
In adolescents with moderate or severe depression, PCPs
should consider consultation with mental health services
and refer to such services when deemed necessary for as-
sessment and/or treatment [13, 23•]. The options for treat-
ment for teens with moderate or severe depression include
psychotherapy and antidepressant treatment provided either
by a mental health specialist or the PCP. While a brief
psychosocial intervention may be attempted, there is evi-
dence that adolescents with moderate-to-severe depression
who do not improve within 2–4 weeks should receive med-
ication and/or psychotherapy [22•].
Psychotherapy
Both CBTand interpersonal therapy (IPT) have been adapted
to address major depressive disorder in adolescents, and
have been shown to be effective in tertiary care, as well as
community settings, such as schools and primary care
[25–27].
CBT is a manual-based, time-limited psychotherapy. It
can be delivered individually or in groups. The focus of
CBT is to change patients’ perceptions of themselves, their
worlds, and the future. CBT treats depression by identifying
behavioral and cognitive patterns that are associated with
depressive cycles. For example, depressed youth frequently
withdraw from their social supports. Additionally, the irrita-
bility that frequently characterizes depression in youth often
results in tension with family members and friends, at a time
when the youth is most in need of social support. CBT
emphasizes activating the youth, increasing participation in
activities that he/she enjoys, developing and/or activating
social skills important for establishing and maintaining pos-
itive social interactions and relationships, and developing
interpersonal problem-solving strategies for resolving stress-
ful problem situations. CBT also aims to correct maladaptive
negative beliefs and thinking patterns that are associated
with increasing depression. For example, an adolescent
who believes that she/he will end up homeless if she/he fails
a test is likely to be depressed as long as she/he is experienc-
ing this cognitive distortion. CBTwould help her/him exam-
ine her/his belief and learn to be realistic about her/his school
performance, even in the face of her/his tendency to
catastrophize. CBT sessions are usually scheduled weekly
for approximately 12–16 weeks. In each session, the thera-
pist and patient complete specific tasks and exercises. Also,
adolescent patients are asked to complete tasks between
sessions.
CBT has been used in primary care with preliminary pos-
itive results [4, 28]. A large RCT in a psychiatric setting
demonstrated superior efficacy of CBT in combination with
fluoxetine when compared with CBTalone [29]. Combination
treatment with CBT and antidepressants has also been shown
to be effective in treatment-resistant depression in adolescents
[30•] and in adolescents with recent suicide attempts [21•].
However, there is also contradictory pragmatic research that
shows CBT in combination with antidepressants to be no
more effective than “routine specialist care” and antidepres-
sant treatment [22•]. Furthermore, there is evidence that after a
longer period of follow-up, treatments with CBT alone, flu-
oxetine alone, and combination treatment converge [31] and
show similarly low rates of deterioration 12 months after
cessation of treatment [32•], suggesting that CBT is a
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reasonable option as monotherapy for adolescent depression.
However, CBT is generally difficult for adolescents with
cognitive problems such as learning disabilities.
IPT for Adolescents (IPT-A), like CBT, is a manual-based
time-limited psychotherapy (12–16 weekly sessions with
optional maintenance treatment). The theoretical foundation
for IPT-A is based on the negative impact of depressive
symptoms on interpersonal relationships and vice versa.
There are a number of considerations to take into account
when deciding whether a patient may be suitable for IPT-A.
First, the patient must be willing to share his/her interper-
sonal experiences, namely conflicts that are ongoing in
his/her relationships. In order to be considered for IPT-A,
the adolescent’s relational problems need to fit into one of
four foci for IPT-A: Grief, Interpersonal Role Disputes,
Interpersonal Role Transitions, and Interpersonal Deficits.
A patient will have a focus of Interpersonal Disputes if they
have important interpersonal relationships that are highly
conflictual. This is the most common focus in IPT-A. The
focus of Role Transition might include starting high school,
reaching puberty, or termination of an important relationship
(e.g., breaking up with a boyfriend, parental divorce or
separation). Adolescents with Interpersonal Deficits tend to
have limited significant interpersonal relationships outside
of their families. The goal of IPT-Awith a focus of Interper-
sonal Deficits is to increase the number of interpersonal
relationships. Prior to referring the patient for IPT-A, the
PCP can do a preliminary assessment for one of the four foci
and give a brief description of IPT-A to patients and their
families. There has not been research conducted to examine
the benefit of combination treatment with IPT-A and antide-
pressant treatment.
Because few PCPs are trained in either of these psycho-
therapies, most psychotherapy will be provided by mental
health professionals. The PCP should be aware of available
community resources for these therapies. Additionally, fami-
lies should be encouraged to ask prospective therapists about
the type of therapy they can provide, the training and super-
vision they have received in pediatric depression, whether
there are specific tasks scheduled for each session (as in
CBT), whether the therapy is time-limited (as in CBT and
IPT), and the goals of therapy.1 Early evidence suggests the
feasibility and efficacy of computerized CBT—this may
emerge as a way to deliver psychotherapy to adolescents in
a cost-effective manner and in resource-poor environments
[33].
Antidepressant Treatment
Previous research shows that up to 42 % of family physicians
in the USA had recently prescribed SSRIs for at least one
adolescent [34]. When indicated by clinical presentation
(clear diagnosis of major depressive disorder) and patient/family
preference, SSRIs should be used [13, 23•].
Table 3 shows the recommended use of antidepressants in
youth with depression [13]. Among the antidepressants, only
fluoxetine has been approved by the Food and Drugs Ad-
ministration (FDA) for use in children and adolescents with
depression. Escitalopram is approved for use by the FDA in
the pediatric population, but only for adolescents aged 12-
years and older. Fluoxetine is the SSRI with the strongest
evidence base for efficacy in the adolescent population, with
four positive RCTs [35]. Two studies involving fluoxetine
for depression have also shown efficacy in children as young
as 7 years of age (range 7–12 years) [36]. This is in contrast
to other SSRIs and newer classes of antidepressants (e.g.,
venlafaxine) where preliminary evidence suggests these
drugs to be more efficacious in older youth. The recent
approval of escitalopram was based on positive findings in
the adolescent subgroups in several studies involving
citalopram and escitalopram. Fluoxetine is the antidepressant
of choice in pediatric depression in the absence of significant
drug–drug interactions, risk factors for bipolar disorder (giv-
en its long half-life and risk among the SSRIs of precipitating
hypomania), family resistance, previous poor response, and
family history of poor response; in these cases, citalopram,
escitalopram, or sertraline may be considered [37].
Medications should be initiated at a low dose and increased in
recommended increments every 1–2 weeks if no significant
adverse effects emerge. Given their rates of increased drug
metabolism, children and adolescents may be at higher risk for
withdrawal symptoms from SSRIs than adults; if these present,
twice-daily dosing may be considered. Fluoxetine has the lon-
gest half-life of the SSRIs and is not generally associated with
withdrawal symptoms between doses or upon discontinuation.
All other SSRIs should be slowly tapered when discontinued.
The patient and family should be informed of the possible
side effects, including possible switch to mania or the devel-
opment of behavioral activation or suicide-related events.
The FDA’s black box warning recommends that physicians
should observe for “clinical worsening, suicidality, and un-
usual changes in behavior” during these initial visits or “at
times of dose changes, either increases or decreases.” Intro-
duction of the warning has significantly decreased the use of
SSRIs in adolescents, and even the rates of diagnosis of
depression in this population [38, 39]. A meta-analysis of
studies of SSRIs in the treatment of pediatric depression
demonstrated a small risk ratio for suicide-related events of
1.66 (95 % confidence interval: 1.02–2.68) and did not find
any completed suicides among study participants [40].
1 Questions to ask prospective therapists adapted by Dr Amy Cheung
from her contributions to the book entitled Adolescent Depression in
Primary Care (Jensen PS, Cheung A, Stein R, Zuckerbrot RA, editors).
New Jersey, USA: Civic Research Institute; 2011.
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Furthermore, some studies have actually demonstrated in-
creases in the rates of adolescent suicide following the black
box warning, although this is controversial [41, 42].
Once the antidepressant is started and tolerated, the physi-
cian should ensure an adequate trial up to the maximum dose
and duration [13]. Contact (in person or by telephone with
either the physician or a member of the clinical staff) should
take place after starting treatment to review the patient’s and
family’s understanding of, and adherence to, the treatment plan.
Medication compliance is noted to be particularly poor in this
population, and significantly predicts treatment outcomes [43].
A regular and frequent monitoring schedule should be devel-
oped, taking care to obtain input from the adolescents and
families to ensure compliance with the monitoring strategy
[13, 44]. Clinicians should also have a system in place to ensure
that follow-up appointments are not missed. This may be done
through flags in patient records or the clinic schedule [45].
The duration of antidepressant treatment in teens with depres-
sion is yet to be determined through clinical trials. However,
based on clinical experience and extrapolation from adult depres-
sion research, most guidelines suggest that antidepressant treat-
ment should be continued for 6–12months after the resolution of
symptoms at the same dosage [44, 46]. The long duration of
treatment can be difficult for patients and families to accept [18].
Patients’ tendency to experience several weeks of side effects at
the initiation of treatment without any improvement in symptoms
can also lead to non-adherence, making education and support
from the PCP and peers critical. Additionally, trials ofmedication
may appear to be more successful during the summer, when
school stress is assumed to be low [47].When possible, treatment
discontinuation should be attempted during a lower stress period.
Depression in Children
Depression in children younger than 12 years of age is less
prevalent than among adolescents; however, it can be reliably
diagnosed in children as young as 3 years of age [48]. There is
significantly less evidence on the treatment of depression in
children than their adolescent counterparts. A meta-analysis
identified seven studies of psychotherapeutic interventions for
children under the age of 13 years with depression, and found
an effect size of 0.41, significantly different from zero
(p=0.03); many of these interventions involved CBT [49]. A
recent trial comparing psychoeducation alone with a parenting
intervention found that both treatments reduced severity of
depression in 3–7-year-olds, but that the parenting interven-
tion demonstrated additional benefit for executive functioning
and emotion-recognition skills [50]. As noted previously, the
only SSRI approved for use in depressed children under the
age of 12 years is fluoxetine. Fluoxetine has demonstrated
benefit for children with depression, and was even found to
be more effective for children under the age of 12 years than
adolescents in one study [36]. The AAFP/US Preventive Ser-
vices Task Force guidelines do caution PCPs that SSRIs, and
fluoxetine, in particular, have “demonstrated harms” in the “risk
of suicidality” in children, and that there is insufficient evidence
to recommend psychotherapy, combination fluoxetine plus
psychotherapy, or routine screening for depression in children.
Clearly, more evidence is required before routine screening for
depression and specific interventions can be recommended in
younger children with depression; PCPs may wish to refer
younger children with depression to mental health specialty
care upon diagnosis.
Conclusions
PCPs are strongly encouraged to manage pediatric depres-
sion to address the unmet mental health needs of children and
adolescents. More importantly, there are a number of guides
and tools available to help family physician take on this task,
including the AACAP practice parameters [44] and the
GLAD-PC toolkit (www.gladpc.org).
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Table 3 Dosing of antidepressants and adverse effects
Medication Starting dose Effective dose Maximum dosage Not to be used with Common adverse effects
Citalopram 10 mg/day 20 mg 40 mg MAOIs QT Headaches, GI upset, insomnia/sedation, prolongation
Fluoxetine 10 mg/day 10 mg 60 mg MAOIs Headaches, GI upset, insomnia, agitation, anxiety
Fluvoxamine 25 mg/day 150 mg 300 mg MAOIs Headaches, GI upset, drowsiness
Sertraline 25 mg/day 50 mg 200 mg MAOIs Headaches, GI upset, insomnia/sedation
Escitalopram 5 mg/day 10–20 mg 20 mg MAOIs Headaches, GI upset, insomnia
MAOIs monoamine oxidase inhibitors, GI gastrointestinal
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